Jean Casner - Embecta Corp Senior Officer
| EMBC Stock | USD 12.46 0.11 0.88% |
Executive
Jean Casner is Senior Officer of Embecta Corp
| Age | 66 |
| Address | 300 Kimball Drive, Parsippany, NJ, United States, 07054 |
| Phone | 862 401 0000 |
| Web | https://www.embecta.com |
Jean Casner Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jean Casner against Embecta Corp stock is an integral part of due diligence when investing in Embecta Corp. Jean Casner insider activity provides valuable insight into whether Embecta Corp is net buyers or sellers over its current business cycle. Note, Embecta Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell Embecta Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jean Casner over three weeks ago Disposition of 227 shares by Jean Casner of CMD at 68.89 subject to Rule 16b-3 |
Embecta Corp Management Efficiency
The company has return on total asset (ROA) of 0.0974 % which means that it generated a profit of $0.0974 on every $100 spent on assets. This is way below average. Embecta Corp's management efficiency ratios could be used to measure how well Embecta Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of June 19, 2024, Return On Tangible Assets is expected to decline to 0.06. In addition to that, Return On Capital Employed is expected to decline to 0.28. At present, Embecta Corp's Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 10.6 M, whereas Total Assets are forecasted to decline to about 1 B.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dr CFA | West Pharmaceutical Services | 57 | |
| Marna BronfenMoore | AngioDynamics | 57 | |
| Jim Ellis | ResMed Inc | N/A | |
| Rajeev Varma | Haemonetics | N/A | |
| YvonneKatrin Pucknat | ResMed Inc | N/A | |
| Juan Serna | AngioDynamics | N/A | |
| Rudy Poussot | West Pharmaceutical Services | N/A | |
| Scott Centea | AngioDynamics | 45 | |
| Kaushik Ghoshal | ResMed Inc | 55 | |
| JoAnne Alkire | Merit Medical Systems | N/A | |
| David Pendarvis | ResMed Inc | 65 | |
| Laurie Miller | Haemonetics | 51 | |
| Brian Lloyd | Merit Medical Systems | 63 | |
| Jan MD | Haemonetics | N/A | |
| Nicholas Khadder | The Cooper Companies | 50 | |
| Saleem Cheeks | AngioDynamics | N/A | |
| Laura Piccinini | AngioDynamics | 55 | |
| Michael Rider | ResMed Inc | 66 | |
| Sarah Comstock | Merit Medical Systems | N/A | |
| Michele Polinsky | West Pharmaceutical Services | N/A | |
Management Performance
| Return On Asset | 0.0974 |
Embecta Corp Leadership Team
Elected by the shareholders, the Embecta Corp's board of directors comprises two types of representatives: Embecta Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Embecta. The board's role is to monitor Embecta Corp's management team and ensure that shareholders' interests are well served. Embecta Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Embecta Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Mann, General VP | ||
| Jean Casner, Senior Officer | ||
| Brian Capone, Chief VP | ||
| Slobodan Radumilo, VP International | ||
| Devdatt Kurdikar, CEO President | ||
| Shaun Curtis, Senior Chain | ||
| Ginny Blocki, Senior Management | ||
| Tom Blount, Senior America | ||
| Ajay Kumar, VP Officer | ||
| Colleen Riley, Senior Officer | ||
| Pravesh Khandelwal, VP Relations | ||
| Jacob Elguicze, Senior CFO |
Embecta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Embecta Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0974 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 2.08 B | ||||
| Shares Outstanding | 57.67 M | ||||
| Shares Owned By Insiders | 0.46 % | ||||
| Shares Owned By Institutions | 98.99 % | ||||
| Number Of Shares Shorted | 2.72 M | ||||
| Price To Earning | 4.91 X | ||||
| Price To Book | 2.61 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Embecta Stock
When determining whether Embecta Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Embecta Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Embecta Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Embecta Corp Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Embecta Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Embecta Stock refer to our How to Trade Embecta Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Embecta Corp. If investors know Embecta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Embecta Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.083 | Dividend Share 0.6 | Earnings Share 1.22 | Revenue Per Share 19.715 | Quarterly Revenue Growth 0.036 |
The market value of Embecta Corp is measured differently than its book value, which is the value of Embecta that is recorded on the company's balance sheet. Investors also form their own opinion of Embecta Corp's value that differs from its market value or its book value, called intrinsic value, which is Embecta Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Embecta Corp's market value can be influenced by many factors that don't directly affect Embecta Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Embecta Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Embecta Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Embecta Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.